Philippe Lambin MD, PhD

Philippe Lambin is a Clinician scientist, Radiation Oncologist, “ERC advanced & twice ERC PoC grant laureate” respectively from 2016, 2017 & 2020 and a pioneer in translational research with a focus on tumor hypoxia;  genetically modified bacteria for cancer treatment and Decision Support Systems. He has a Ph.D. in Molecular Radiation Biology and is a Professor at the University of Maastricht (Precision Medicine) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is a co-author of more than 579 peer-reviewed scientific papers (https://orcid.org/0000-0001-7961-0191, more than 43K citations, Hirsch Index: 110  Google scholar; i-10 index: 482, co-inventor of more than 22 patent families (filed or submitted) of which 10 are in the (pre)commercialization phase and (co) promoter of more than 66 completed Ph.D.’s.

His main areas of interest are directed toward translational research in tumor Biology with a specific focus on tumor hypoxia, functional imaging (Radiomics), and lung and head and neck cancer. More recently, his interests have been directed towards hypoxia targeting, Hypoxia Activated Prodrugs, during immunotherapy, genetically modified bacteria as living medicine and the development of an “AI-based treatment decision support system” based on multiparametric databases containing clinical, imaging, biological, and therapeutic information, and taking into account patient preferences. The website he launched, predictcancer.org or ai4cancer.ai with validated predictive models has had more than 20.000 visitors from more than 133 countries.

He is one of the co-inventor of “Radiomics”, “Clinical Decision Support Systems”, “Distributed learning” from federated databases, genetically modified bacteria for cancer treatment, the combination of immune cytokines with radiation, Lymphocytes-Sparing Radiotherapy (LSRT, also named “Drugless Radiotherapy”) and MEDomics.